NASDAQ : OCGN
Ocugen, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.7027 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 238.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 245.75M |
| Enterprise Value | 233.69M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 339.11M |
| Shares Outstanding | 339.11M |
| Shares Change (YoY) | +11.22% |
| Shares Change (QoQ) | +3.40% |
| Owned by Insiders (%) | 1.42% |
| Owned by Institutions (%) | 43.29% |
| Float | 334.30M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 54.79 |
| Forward PS | 70.90 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 52.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.80 |
| Quick Ratio | 0.75 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.16 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -48.44% |
| Return on Invested Capital (ROIC) | -80.26% |
| Return on Capital Employed (ROCE) | 776.45% |
| Weighted Average Cost of Capital (WACC) | 14.35% |
| Revenue Per Employee | $39,491 |
| Profits Per Employee | -$705,267 |
| Employee Count | 116 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.27 |
| 52-Week Price Change | -53.54% |
| 50-Day Moving Average | 1.02 |
| 200-Day Moving Average | 1.42 |
| Relative Strength Index (RSI) | 33.36 |
| Average Volume (20 Days) | 7,012,811 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 107.16M |
| Short Previous Month | 102.05M |
| Short % of Shares Out | 31.60% |
| Short % of Float | 32.05% |
| Short Ratio (days to cover) | 14.33 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.58M |
| Gross Profit | -39.18M |
| Operating Income | -68.90M |
| Pretax Income | -81.81M |
| Net Income | -81.81M |
| EBITDA | -67.17M |
| EBIT | -68.90M |
| Loss Per Share | -$0.26 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 100.05M |
| Total Debt | 87.99M |
| Net Cash | 12.07M |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | -16.56M |
| Book Value Per Share | -0.05 |
| Working Capital | -26.36M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -60.87M |
| Capital Expenditures | -153,000 |
| Depreciation & Amortization | 1.73M |
| Net Borrowing | 84.26M |
| Free Cash Flow | -61.02M |
| FCF Per Share | -$0.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,504.08% |
| Pretax Margin | -1,785.88% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.22% |
| Shareholder Yield | -11.22% |
| Earnings Yield | -35.20% |
| FCF Yield | -24.31% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $12.17 |
| Price Target Difference | 1,579.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 221.83% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -5.17 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |